CG Oncology, Inc. (CGON)
| Market Cap | 6.97B +147.9% |
| Revenue (ttm) | 6.23M +1,030.3% |
| Net Income | -224.38M |
| EPS | -2.72 |
| Shares Out | 88.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 384,378 |
| Open | 78.31 |
| Previous Close | 78.25 |
| Day's Range | 77.73 - 80.63 |
| 52-Week Range | 35.64 - 80.97 |
| Beta | 0.24 |
| Analysts | Strong Buy |
| Price Target | 91.08 (+15.76%) |
| Earnings Date | Aug 6, 2026 |
About CGON
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with... [Read more]
Financial Performance
In 2025, CG Oncology's revenue was $4.04 million, an increase of 254.70% compared to the previous year's $1.14 million. Losses were -$161.00 million, 82.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CGON stock is "Strong Buy." The 12-month stock price target is $91.08, which is an increase of 15.76% from the latest price.
News
CG Oncology Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Key highlights include robust BLA progress for cretostimogene grenadenorepvec, strong differentiation through durable efficacy and operational simplicity, and a well-capitalized position supporting multiple clinical and commercial milestones. Near-term catalysts include pivotal trial data and label expansion opportunities.
CG Oncology Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Cretostimogene is advancing through multiple late-stage trials for non-muscle invasive bladder cancer, with a new phase III in BCG-exposed patients and imminent PIVOT-006 results. Manufacturing and regulatory preparations are nearly complete, and market adoption strategies focus on workflow compatibility and leveraging real-world data.
CG Oncology to Present at Upcoming Investor Conferences in September
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentat...
CG Oncology price target raised to $85 from $82 at Truist
Truist raised the firm’s price target on CG Oncology (CGON) to $85 from $82 and keeps a Buy rating on the shares.
CG Oncology price target lowered to $79 from $81 at RBC Capital
RBC Capital lowered the firm’s price target on CG Oncology (CGON) to $79 from $81 and keeps an Outperform rating on the shares.
CG Oncology reports Q2 EPS (90c), consensus (64c)
Reports Q2 revenue $1.16M, consensus $362,640. “This quarter we have made significant progress across our clinical, regulatory, manufacturing and commercial-readiness initiatives, positioning the Comp...
CG Oncology Earnings release: Q2 2026
CG Oncology released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
CG Oncology Quarterly report: Q2 2026
CG Oncology has published its Q2 2026 quarterly earnings report on August 6, 2026.
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
CG Oncology announces publication of BOND-003 results in The Lancet Oncology
CG Oncology (CGON) announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calm...
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder ...
CG Oncology Slides: Investor presentation
CG Oncology has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
CG Oncology Slides: Conference presentation
CG Oncology has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
CG Oncology 1.15M share Block Trade priced at $66.87
The deal range was $66.87-$67.87. Morgan Stanley acted as sole book running manager for the offering.
CG Oncology 1.15M share Block Trade; price range $66.87-$67.87
Morgan Stanley is acting as sole book running manager for the offering.
CG Oncology Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Cretostimogene is advancing in pivotal trials for NMIBC, with strong clinical durability and differentiation versus competitors. Regulatory and manufacturing processes are aligned for upcoming filings, and commercial strategy targets key accounts with a robust financial runway through 2029.
CG Oncology Transcript: Jefferies Global Healthcare Conference 2026
Cretostimogene is advancing as a differentiated oncolytic immunotherapy for NMIBC, showing strong durability and safety data, with a rolling BLA submission underway and commercial preparations progressing. Key upcoming milestones include pivotal trial data and expansion into broader patient populations.
CG Oncology to Present at Upcoming Investor Conferences in June
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentatio...
CG Oncology announces departure of president, COO Ambaw Bellete
In a regulatory filing, CG Oncology (CGON) announced that on May 20, the company and Ambaw Bellete, the company’s President & COO, agreed to his separation from the company to…
Wolfe sees CG Oncology COO exit as operational, no impact to key programs
Wolfe Research notes that CG Oncology (CGON) announced the departure of the company’s COO Ambaw Bellete this morning. The departure sounds more operational in nature and is not indicative of…
CG Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026
Recent data show cretostimogene plus gemcitabine offers higher efficacy and strong safety in BCG-exposed NMIBC, informing a phase III trial. Manufacturing and regulatory progress support a BLA filing by year-end, with launch readiness and broad clinical integration underway.
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year's awa...
CG Oncology initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of CG Oncology (CGON) with a Peer Perform rating. CG Oncology faces key upcoming catalysts from its PIVOT-006 Phase 3 readout in intermediate-risk Non-Muscle Invasive...
CG Oncology reports first results from CORE-008 Cohort CX
CG Oncology (CGON) announced first results from CORE-008 Cohort CX, a Phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent ...
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively